Source link : https://newshealth.biz/health-news/doublet-shows-activity-in-rare-aggressive-kidney-cancer/
(MedPage Today) — Bevacizumab (Avastin) combined with erlotinib (Tarceva) showed activity in patients with hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated or sporadic papillary renal cell carcinoma (RCC), a phase II trial suggested… Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/116149 Author : Publish date : 2025-06-18 21:00:00 Copyright for syndicated content belongs to the linked Source.
The post Doublet Shows Activity in Rare, Aggressive Kidney Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-18 21:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8